Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male subject aged 18 to 65 years inclusive~* BMI \> 30 kg/m2 and \< 50 kg/m2~* Serum total testosterone concentration below the normal range~* LH levels below the upper limit of normal~* Oestradiol levels within or above the normal range of approved assay~* At least two symptoms of androgen deficiency present for at least 2 months prior to the first Screening Visit, with at least one of these being a sexual dysfunction~Exclusion Criteria:~* Evidence of clinically significant endocrinopathy at screening that may interfere with the study assessments~* Other types of hypogonadotropic hypogonadism or primary hypogonadism~* Any other pituitary or hypothalamic disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BGS649 0.1 mg (Type: EXPERIMENTAL): BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
- BGS649 0.3 mg (Type: EXPERIMENTAL): BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
- BGS649 1.0 mg (Type: EXPERIMENTAL): BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo weekly (3 indistinguishable placebo capsules)

Based on this trial design, predict the completion outcome and termination type (if applicable).